MENU
RMD
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

RMD stock forecast, quote, news & analysis

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
a Summary for RMD with price predictions
Nov 10, 2026

RMD in downward trend: price may drop because broke its higher Bollinger Band on October 15, 2026

RMD broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 42 similar instances where the stock broke above the upper band. In 32 of the 42 cases the stock fell afterwards. This puts the odds of success at 76%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for RMD moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 24 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.

The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RMD as a result. In 64 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.

The Moving Average Convergence Divergence Histogram (MACD) for RMD turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 29 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 38 of 57 cases where RMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.

RMD moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for RMD crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.

The 50-day moving average for RMD moved above the 200-day moving average on October 08, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +3.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where RMD advanced for three days, in 181 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.

The Aroon Indicator entered an Uptrend today. In 133 of 218 cases where RMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 40 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. RMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.154) is normal, around the industry mean (4.964). P/E Ratio (22.474) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (4.143). Dividend Yield (0.011) settles around the average of (0.005) among similar stocks. P/S Ratio (5.896) is also within normal values, averaging (56.876).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Dividends

RMD paid dividends on September 24, 2026

ResMed RMD Stock Dividends
А dividend of $0.66 per share was paid with a record date of September 24, 2026, and an ex-dividend date of August 20, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.78B. The market cap for tickers in the group ranges from 126 to 159.96B. ISRG holds the highest valuation in this group at 159.96B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 0%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 20%. ZJYL experienced the highest price growth at 55%, while NXGL experienced the biggest fall at -20%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -27%. For the same stocks of the Industry, the average monthly volume growth was 17% and the average quarterly volume growth was -24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 53
Price Growth Rating: 49
SMR Rating: 81
Profit Risk Rating: 93
Seasonality Score: 21 (-100 ... +100)
RMD in downward trend: price may drop because broke its higher Bollinger Band on October 15, 2026